EFFECT OF CLOMIFENE ON THYROID FUNCTION IN NORMAL MEN

1979 ◽  
Vol 90 (1) ◽  
pp. 43-51 ◽  
Author(s):  
Ulla Feldt-Rasmussen ◽  
Axel P. Lange ◽  
John Date ◽  
Mogens Kern Hansen
Keyword(s):  
Thyroid Hormone ◽  
Thyroid Function ◽  
Binding Proteins ◽  
Serum Concentrations ◽  
Hormone Binding ◽  
Free Thyroxine Index ◽  
Group 2 ◽  
Uptake Test ◽  
Normal Men ◽  
Group 1

ABSTRACT To study the effect on thyroid function 100 mg of clomifene citrate was given once a day to two groups of healthy male volunteers for 5 and 12 consecutive days, respectively. In both groups serum concentrations of TSH, thyroxine, triiodothyronine, T3 resin uptake test and thyroid hormone binding proteins were measured before, during and after oral administration of clomifene. The effect of clomifene treatment was evaluated in Group 1 by means of serum FSH and LH measurements. Further in Group 2 the serum TSH response to iv TRH (200 μg) was also investigated. The mean per cent elevations in serum concentrations of FSH and LH were 145 and 200, respectively. In Group 1 a small but statistically significant decrease within reference limits in triiodothyronine (P < 0.01) and free thyroxine index (P < 0.02) was found on day 4 of clomifene. On day 5 a slight increase in TSH was observed (P < 0.05). In Group 2 the response of TSH to TRH showed a non-significant increase after 5 days and a significant increase (P < 0.01) after 12 days of clomifene. Eight days after discontinuation of the drug the response was restored to normal. No changes in the thyroid hormone binding proteins in serum could be demonstrated. Though the observed changes were slight, they indicate that clomifene exerts an influence directly on the thyroid function.

scholarly journals Concentration of Serum Thyroid Hormone Binding Proteins after 131I Treatment of Hyperthyroidism

1981 ◽  
Vol 18 (4) ◽  
pp. 211-214 ◽  
Author(s):  
John S Harrop ◽  
Malcolm R Hopton ◽  
John H Lazarus
Keyword(s):  
Thyroid Hormone ◽  
Binding Proteins ◽  
Response To Treatment ◽  
Serum Concentrations ◽  
Hormone Binding ◽  
Thyroxine Binding Globulin ◽  
131I Treatment ◽  
Before And After ◽  
Hormone Binding Protein ◽  
Serum Thyroid Hormone

Serum concentrations of the thyroid hormone binding proteins, thyroxine binding globulin, prealbumin, and albumin were determined in 30 thyrotoxic patients before and after 131I treatment. Each patient was placed into one of three groups according to response to treatment. The serum concentration of all three proteins rose significantly in 10 patients who became euthyroid, and a greater increase was seen in 10 patients who developed hypothyroidism. There was no significant change in thyroid hormone binding protein concentrations in 10 subjects who remained hyperthyroid. Changes in the concentration of thyroid hormone binding proteins should be borne in mind when total thyroid hormone concentrations are used to monitor the progress of patients receiving treatment for hyperthyroidism.

Indirect estimation of thyroid hormone-binding proteins to calculate free thyroxine index: comparison of nonisotopic methods that use labeled thyroxine ("T-uptake")

1995 ◽  
Vol 41 (1) ◽  
pp. 41-47 ◽  
Author(s):  
J D Faix ◽  
H N Rosen ◽  
F R Velazquez
Keyword(s):  
Thyroid Hormone ◽  
Binding Proteins ◽  
Free Thyroxine ◽  
Reference Ranges ◽  
Hormone Binding ◽  
Free T4 ◽  
Nonthyroidal Illness ◽  
Free Thyroxine Index ◽  
Uptake Method ◽  
Hypothyroid Patients

Abstract There are many alternative ways of estimating free thyroxine (T4) when thyrotropin screening results are abnormal. In addition to free T4 immunoassays, the menu of most automated immunoassay instruments includes a nonisotopic version of the original triiodothyronine (T3)-uptake assay called "T-uptake." We evaluated the ability of five such assays (Access, ES-300, IMx, Magnum Opus, and Stratus) to accurately estimate the free thyroxine index (FTI) in euthyroid, hyperthyroid, and hypothyroid patients with abnormal concentrations of thyroid hormone-binding proteins, and in patients with nonthyroidal illness. For comparison, we calculated a similar FTI, using either T3-uptake or direct measurement of thyroxine-binding globulin (TBG). Euthyroid reference ranges were comparable. Of euthyroid patients with increased TBG, 12-32% and 5-20% had increased or suppressed FTI, respectively, depending on the T-uptake method used. Except for IMx, 6-35% of hypothyroid patients with increased TBG had inappropriately increased FTI. Patients with nonthyroidal illness had comparable results regardless of the method used, and T-uptake methods were variably affected by known inhibitors of thyroid hormone binding. The most reliable T-uptake method appeared to be the IMx, which, despite claims that it measures all thyroid hormone-binding proteins, correlated best with TBG concentrations.

Dose related effects of betamethasone on iodothyronines and thyroid hormone-binding proteins in serum

1981 ◽  
Vol 96 (4) ◽  
pp. 484-490 ◽  
Author(s):  
Anders Gamstedt ◽  
Gunnar Järnerot ◽  
Bertil Kågedal
Keyword(s):  
Thyroid Hormone ◽  
Healthy Volunteers ◽  
Thyroid Function ◽  
Dose Response ◽  
Binding Proteins ◽  
Response Pattern ◽  
Thyroid Function Tests ◽  
Hormone Binding ◽  
Clear Cut ◽  
Oral Corticosteroids

Abstract. Earlier studies of the effect of glucocorticoids on thyroid function tests have given different results. This may be due to the fact that varying corticosteroid doses have been used. The present study examines four groups of healthy volunteers, who were given betamethasone in increasing doses (1.5, 3.0, 4.5 and 6.0 mg daily) for 5 days. Definite dose-response relations were found for serum T4 and T3 while no clear-cut dose-response pattern was found for rT3. The results obtained explain previous variable results. Oral corticosteroids also affected the concentrations of the thyroid hormone-binding proteins but no clear-cut dose-response relation were observed.

ENDOCRINE CHANGES BEFORE AND AFTER THE MENARCHE

1973 ◽  
Vol 74 (4) ◽  
pp. 685-694 ◽  
Author(s):  
B.-A. Lamberg ◽  
R.-L. Kantero ◽  
P. Saarinen ◽  
O. Widholm
Keyword(s):  
Binding Proteins ◽  
Maturation Process ◽  
Hormone Binding ◽  
Maximal Level ◽  
Continuous Increase ◽  
Mean Values ◽  
Thyroxine Binding Globulin ◽  
Before And After ◽  
Free Thyroxine Index ◽  
Level 1

ABSTRACT In an endocrine survey of healthy girls aged 8 to 20 years before and after the menarche, the serum thyroxine (T4), uptake of triiodothyronine by Sephadex (T3U), and the binding capacities of thyroxine binding globulin (TBG) and pre-albumin (TBPA) were measured, and a free thyroxine index (FTI = T4 × T3U) was calculated. The subjects were grouped according to skeletal age (SA) until the menarche and after this in the post-menarcheal age (PMA), expressed in years. T4 and FTI increased concomitantly and reached peak values of 8.40 μg/100 ml and 8.40, respectively, at 2–3 years PMA. The corresponding mean values for post-menarcheal girls (7.74 μg/100 ml and 7.51) differed statistically significantly from the means before the menarche (7.03 μg/ 100 ml and 6.75). The TBG remained virtually unchanged during the whole period, whereas the TBPA showed a continuous increase and reached a maximal level 1–2 years after the menarche. The maturation process in girls in some way involves an increase in the total and free T4 level which is not dependent on hormone binding proteins.

scholarly journals Studies on Cytosol Thyroid Hormone Binding Proteins in Rat Liver

1987 ◽  
Vol 63 (1) ◽  
pp. 69-76
Author(s):  
Masataka NANNO ◽  
Hirotoshi NAKAMURA ◽  
Satoshi HAMADA ◽  
Teruya YOSHIMI ◽  
Hiroo IMURA ◽  
...  
Keyword(s):  
Thyroid Hormone ◽  
Rat Liver ◽  
Binding Proteins ◽  
Hormone Binding

scholarly journals Pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal anti-SARS-CoV-2 antibody, for COVID-19-related moderate pneumonia: a randomized, double-blind, placebo-controlled, phase IIa study

2021 ◽  
Author(s):  
Benjamin Gaborit ◽  
Eric Dailly ◽  
Bernard Vanhove ◽  
Régis Josien ◽  
Karine Lacombe ◽  
...  
Keyword(s):  
Adverse Events ◽  
High Serum ◽  
Serum Concentrations ◽  
Serious Adverse Events ◽  
Double Blind ◽  
Good Tolerability ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

Objective: We assessed the pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2, in COVID-19-related moderate pneumonia. To evaluate the optimal dose and safety of XAV-19 during this first administration to patients with COVID-19-related moderate pneumonia. Methods : In this phase 2a trial, adults with COVID-19-related moderate pneumonia of ≤10 days duration were randomized to infusion of XAV-19 0.5mg/kg at day 1 and day 5 (group 1), 2mg/kg at day 1 and day 5 (group 2), 2mg/kg at day 1 (group 3) or placebo. Results : Eighteen patients (n=7 for group 1, n=1 for group 2, n=5 for group 3, and n=5 for placebo) were enrolled. Baseline characteristics were similar across groups, XAV-19 serum concentrations (μg/mL, median, range) at C max and at day 8 were 9.1 (5.2-18.1) and 6.4 (2.8-11.9), 71.5 and 47.2, and 50.4 (29.1-55.0) and 20.3 (12.0-22.7) for groups 1, 2 and 3, respectively (p=0.012). Terminal half-life (median, range) was estimated at 11.4 (5.5-13.9) days for 2 mg/kg of XAV-19 at day 1. Serum XAV-19 concentrations were above the target concentration of 10 μg/mL (tow fold the in vitro 100% inhibitory concentration [IC 100 ]) from the end of perfusion to more than 8 days for XAV-19 2 mg/kg at day 1. No hypersensitivity or infusion-related reactions were reported during treatment, there was no discontinuation for adverse events and no serious adverse events related to study drug. Conclusions : Single intravenous dose of 2mg/kg of XAV-19 demonstrated high serum concentrations, predictive of potent durable neutralizing activity with good tolerability. Trial registration: ClinicalTrials.gov Identifier: NCT04453384

Sign in / Sign up

Export Citation Format

Share Document